LUCD | Lucid Diagnostics Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.3600 - 1.4200
52 Week Range	0.6300 - 1.6330
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	327,744
Average Volume	558,050
Shares Outstanding	59,342,480
Market Cap	82,486,047
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2021-10-14

Valuation
Profitability
Growth
Health
P/E Ratio	-1.24
Forward P/E Ratio	-1.03
EPS	-1.12
1YR Price Target	3.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	70
Country	USA
Website	LUCD

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

LUCD's peers: BFLY, NARI, XAIR, PAVMZ, CLPT, OSA, LIVN, ELMD, KIDS, SRDX, NPCE, FNA, CVRX, LUNG, IRMD, OFIX, ITGR, SRTS

*Chart delayed

Analyzing fundamentals for LUCD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see LUCD Fundamentals page.

Watching at LUCD technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on LUCD Technicals page.